Medical Device Preclinical Bootcamp

Size: px
Start display at page:

Download "Medical Device Preclinical Bootcamp"

Transcription

1 Medical Device Preclinical Bootcamp March 30, :30am - 2:30pm Massachusetts Biotechnology Council (MassBio) 300 Technology Square, 8th Floor Cambridge, MA Featured Speakers Rosalyn Año Laurence Lister Stephen Doherty, Ph.D. Kevin Connor, Ph.D., DABT Russell Sloboda Bootcamp Coverage The Basics of Biocompatibility Testing Chemical Characterization of Medical Devices: Strategies, Pitfalls, and Points of Consideration Toxicological Risk Assessment Based on Extractable/Leachable Data: Why, When, and How Toxicological Risk Assessment for Breathing Gas Pathway Medical Devices: ISO and ISO Tips for a Successful Sponsor-Laboratory Partnership

2 Medical Device Preclinical Bootcamp 9:30 10:00: Registration 10:00 10:15: Welcome and Introduction: The Medical Device Approval Pathway 10:15 11:45: The Basics of Biocompatibility Testing The Basics of Biocompatibility Testing Biocompatibility simply refers to the properties of materials being biologically compatible by not eliciting local or systemic responses from a living system or tissue. This presentation will discuss the basics of biocompatibility testing. This presentation will discuss the history and evaluation of biocompatibility. It will explain how to properly classify your device. Then when biological endpoints are applicable for the properly labeled device will be covered. Finally, a high level discussion of each biological evaluation and the various choices will be explained. 11:45 12:15: Lunch and Networking 12:15 1:00: Chemical Characterization of Medical Devices: Strategies, Pitfalls, and Points of Consideration Recent regulatory guidance documents have emphasized the need for chemical characterization of medical devices as part of an overall device assessment. We will examine the types of information available from a chemical characterization and how to get the information you are looking for from the testing. Strategies for study design and execution will be discussed. Common pitfalls and potential shortcomings and how to avoid them will also be presented. 1:00 2:00: Toxicological Risk Assessment Based on Extractable/Leachable Data: Why, When, and How Toxicological Risk Assessment (TRA) has been an important tool in the safety assessment of biomedical devices, providing a chemical-based approach which complements a more traditional testing program largely based on whole animal studies. The need for TRA is growing and in some cases, will be considered as a means of circumventing animal testing in the safety evaluation of devices. TRA is founded on the notion that, if all constituents of a product, including additive, impurities and contaminants, are known, then the safety (or risk) of a product can be assessed based on the toxicology of those constituents, ascertained through extractable / leachable (E/L) studies. However, the E/L analysis can face several pitfalls towards achieving the objectives of risk assessment and current regulatory guidance leaves the analyst having to make many choices based on their own judgment. However, this shortcoming of the data can be avoided with proper study design. Potential pitfalls in the E/L analysis will be discussed together some tested methods for their avoidance, which will be illustrated with case studies. 2:00 2:20: Toxicological Risk Assessment for Breathing Gas Pathway Medical Devices: ISO and ISO 1856 Breathing gas pathway medical devices such as breathing systems, ventilators, anesthesia systems, nebulizers and oxygen lines come into contact with patients at a particularly vulnerable point and time. Bootcamp Agenda

3 Bootcamp Agenda Medical Device Preclinical Bootcamp As a result, the exposure assessment for these devices is an important step in the evaluation of device safety and needs to be particularly concerned with airborne releases, especially volatile organic compound (VOCs). ISO and ISO may both apply; yet in some instances each standard recommends a very different technical approach to the measurement of releasable chemicals and different assumptions for the risk assessment. The key differences in these two methodologies will be illustrated, along with an analysis of how different risk estimates derived using these regulatory guidelines points out the need to justify the use of one over the other. 2:20 2:35: Tips for a Successful Sponsor-Laboratory Partnership With over 40 years of experience and having completed thousands of studies, Toxikon has seen the good, the bad, and the ugly of medical device safety and efficacy testing. With our customers, collectively we ve learned how proper preparation, comprehensive communication, and clear expectations on both sides creates an environment where studies are initiated efficiently and completed effectively. We will facilitate an open discussion sharing what we ve learned about creating a successful partnership between the sponsoring company and the contract laboratory, to help your next project have the best chance for success.

4 Medical Device Preclinical Bootcamp Rosalyn Año Business Development Manager Stephen Doherty, Ph.D. Director of Analytical Chemistry Workshop Faculty Rosalyn has more than 10 years of experience in guiding medical device companies through successful product safety testing strategies. As one of Toxikon s business development managers, she has a track record of controlling study costs through sound risk management techniques, reducing the probability of test failure, and streamlining product development timelines to achieve key milestones ultimately resulting in a high success rate of getting high quality and safe products to market. Rosalyn received her B.S. in Biomedical Engineering from Boston University. Laurence Lister Director of Biocompatibility Laurence has over 25 years of experience in every aspect of biocompatibility and toxicology testing. As Toxikon s head of biocompatibility, he is responsible for the direction of the staff of scientists that perform thousands of biocompatibility studies each year. Laurence has authored several papers on the specifics of biocompatibility tests, and is a member of several national and international committees that steer biocompatibility regulation and guidance. Laurence received his B.S. in Biology from Boston College. Stephen has more than 20 years of experience in chemical testing and characterization of medical devices and related products. As Toxikon s director of analytical chemistry, he develops experimental study designs to address client-specific test and regulatory requirements. Dr. Doherty is the author of a number of articles and book chapters on polymer formulation, testing, and applications, and is a frequent presenter on extractable / leachable topics at industry conferences around the country each year. Stephen received his B.A. in Chemistry from Colby College and a Ph.D. in Analytical Chemistry from the University of New Hampshire.

5 Workshop Faculty Medical Device Preclinical Bootcamp Kevin Connor, Ph.D., DABT Director of ToxSMART Consulting Practice Kevin has more than 20 years of experience in toxicology and human health risk assessment within a variety of regulatory frameworks. As head of Toxikon s risk assessment consulting division, ToxSMART, he has managed hundreds of risk assessments for medical devices and consumer products, including assessments under ISO Dr. Connor works closely with Toxikon s analytical laboratories in procuring the most relevant data from extractability leachability (E/L) analyses to best help sponsors develop methods that carefully consider the nature of consumer exposure. Russell Sloboda Study Director ToxSMART Consulting Practice Russell Sloboda is an analytical chemist and risk assessment specialist with 35 years experience. At Toxikon he is responsible for all aspects of toxicological risk assessment as per ISO and ICH M7 guidelines, which includes literature research, exposure modeling, investigation of medical device and drug product manufacturing practice and usage, application of QSAR models to screen chemical toxicity, development of toxicological profiles, and calculation of tolerable intakes based on extrapolation of animal toxicity data. He communicates effectively and provides consulting support in analytical study design, specification of AETs, and response to FDA comments.

6 Medical Device Preclinical Bootcamp Registration Information: Online: Venue Information: Massachusetts Biotechnology Council (MassBio) 300 Technology Square, 8th Floor Cambridge, MA Directions / Parking: Accessible via the MBTA at the Kendall Square stop, Red Line. Parking available at Technology Square Garage, 595 Technology Square, Cambridge, MA Registration

Biocompatibility Testing for Medical Devices

Biocompatibility Testing for Medical Devices Biocompatibility Testing for Medical Devices *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! The medical device field is one of the most heavily regulated industries, for obvious

More information

Biocompatibility Testing for Medical Devices

Biocompatibility Testing for Medical Devices Biocompatibility Testing for Medical Devices *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! The medical device field is one of the most heavily regulated industries, for obvious

More information

NAMSA is a Medical Research Organization (MRO), accelerating product development

NAMSA is a Medical Research Organization (MRO), accelerating product development NAMSA is a Medical Research Organization (MRO), accelerating product development through integrated laboratory, clinical and consulting services. Driven by our regulatory expertise, NAMSA's MRO Approach

More information

Safety Qualification Process and Application of Thresholds. Jim Blanchard PQRI L&E Toxicology Subgroup Principal Scientist Aradigm

Safety Qualification Process and Application of Thresholds. Jim Blanchard PQRI L&E Toxicology Subgroup Principal Scientist Aradigm Safety Qualification Process and Application of Thresholds Jim Blanchard PQRI L&E Toxicology Subgroup Principal Scientist Aradigm Outline Safety qualification process What to do when leachables exceed:

More information

ISO Series Biocompatibility evaluation of breathing gas pathways in healthcare applications

ISO Series Biocompatibility evaluation of breathing gas pathways in healthcare applications ISO 18562 Series Biocompatibility evaluation of breathing gas pathways in healthcare applications James Morrison LIVE WEBINAR November 2018 2018 Brandwood Biomedical www.brandwoodbiomedical.com James (Morrison)

More information

Addressing challenges in Drug Development and Quality Control with innovative solutions

Addressing challenges in Drug Development and Quality Control with innovative solutions Addressing challenges in Drug Development and Quality Control with innovative solutions SYNOPSIS 16 May 2013, 9:30 am 3:00 pm Gd. Titan Centre (Theater Room) This seminar is designed for scientists in

More information

BIOCOMPATIBILITY TESTING OF GAS PATHWAYS IN MEDICAL DEVICES

BIOCOMPATIBILITY TESTING OF GAS PATHWAYS IN MEDICAL DEVICES BIOCOMPATIBILITY TESTING OF GAS PATHWAYS IN MEDICAL DEVICES EXECUTIVE SUMMARY Many medical devices used to assist in the diagnosis, monitoring or treatment of respiratory issues or to deliver anesthesia

More information

Colorants in Medical Devices:

Colorants in Medical Devices: Colorants in Medical Devices: The Spectrum of Current Regulatory Expectations John Iannone Program Manager/ Technical Specialist Overview» Company Introduction» Why use Colorants in Devices?» Regulatory

More information

Design Perspectives on. Drug/Biologic Delivery. Medtronic Neuromodulation. Luis Fesser Deanna Lane Jeanmarie Sales July 16, 2012

Design Perspectives on. Drug/Biologic Delivery. Medtronic Neuromodulation. Luis Fesser Deanna Lane Jeanmarie Sales July 16, 2012 Design Perspectives on Implantable Devices for Targeted Drug/Biologic Delivery Medtronic Neuromodulation Steve Christenson Luis Fesser Deanna Lane Jeanmarie Sales July 16, 2012 The following presentation

More information

Satisfying ISO and US FDA Biocompatibility requirements for Breathing Gas Pathways in Healthcare Application

Satisfying ISO and US FDA Biocompatibility requirements for Breathing Gas Pathways in Healthcare Application Satisfying ISO 18562 and US FDA Biocompatibility requirements for Breathing Gas Pathways in Healthcare Application Audrey Turley, B.S., RM (NRCM), CBA Biocompatibility Expert 801-290-7907 aturley@nelsonlabs.com

More information

Introduction to clinical trials Magnus Kjaer

Introduction to clinical trials Magnus Kjaer Introduction to clinical trials 2016-01-20 Magnus Kjaer One Definition of Clinical Trial NIH 2014 A research study in which one or more human subjects are prospectively assigned to one or more interventions

More information

Derivation and Justification of Safety Thresholds

Derivation and Justification of Safety Thresholds Derivation and Justification of Safety Thresholds Douglas J. Ball, MS, DABT Chair, PQRI L&E Toxicology Subgroup Research Fellow, Safety Sciences - Pfizer, Inc. Agenda Basic Definitions Current Regulatory

More information

Introduction to clinical trials

Introduction to clinical trials Introduction to clinical trials Definition of a clinical trial A research activity that involves administration of a test treatment to some experimental unit in order to evaluate the treatment. Key words

More information

From Bench to Bedside. Russ H. Read June 23, 2014

From Bench to Bedside. Russ H. Read June 23, 2014 From Bench to Bedside Russ H. Read June 23, 2014 Talent Required Scientists, clinicians, technicians, chemists, biologists, pharmacologists, toxicologists, research associates, regulatory experts, manufacturing

More information

Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development

Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality

More information

FUTURE MEANS CREATIVITY

FUTURE MEANS CREATIVITY START-UP & ACADEMICS THEORY & PRACTICE IN DRUG DEVELOPMENT 1 EARLY PHASE DRUG DEVELOPMENT COURSE MAY 9 TH 2017 - ANTWERP FUTURE MEANS CREATIVITY VENUE: LINDNER HOTEL LANGE KIEVITSTRAAT 125 BE-2018 ANTWERP,

More information

Extractables and Leachables in Early Phase Development

Extractables and Leachables in Early Phase Development Extractables and Leachables in Early Phase Development Wayland Rushing, Ph.D. Senior Scientific Advisor, ABC 11/23/2015 Product and Process Variants & Impurities 1 Regulatory Perspective Dr. Ingrid Markovic,

More information

Extractables & Leachables Boston 2019 Ensuring Quality, Safety, Suitability and Regulatory Compliance for Drugs, Biologics and Medical Devices

Extractables & Leachables Boston 2019 Ensuring Quality, Safety, Suitability and Regulatory Compliance for Drugs, Biologics and Medical Devices Ensuring Quality, Safety, Suitability and Regulatory Compliance for Drugs, Biologics and Medical Devices April 10 11, 2019, Metro Meeting Centers, Boston, MA Featuring Lessons Learned and Case Studies

More information

Extractables and leachables: An Introduction

Extractables and leachables: An Introduction Extractables and leachables: An Introduction Tim Hulme Smithers Rapra THulme@smithers.com 44(0)1939 252 418 1 Extractables and leachables: An Introduction Tim Hulme Smithers Rapra thulme@smithers.com 2

More information

Drug Impurities: The Good, Bad and Ugly

Drug Impurities: The Good, Bad and Ugly Drug Impurities: The Good, Bad and Ugly Joel Bercu, PhD, DABT, MPH Associate Director, Environmental and Occupational Toxicology Gilead Sciences jbercu@gilead.com Medicines Impurities 2015-2016 GrimsrudBerkowitz

More information

Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH)

Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY!

More information

How to Prepare MedDevice Packaging for Regulatory Success A Chemical Characterization (E&L) Perspective

How to Prepare MedDevice Packaging for Regulatory Success A Chemical Characterization (E&L) Perspective How to Prepare MedDevice Packaging for Regulatory Success A Chemical Characterization (E&L) Perspective Frank Bieganousky, AMRI Wei Zhang, Ph.D., AMRI Purpose» Demonstrate a proactive approach for integration

More information

INVESTIGATIONS BOOTCAMP NIBRT (NATIONAL INSTITUTE FOR BIO-PROCESSING RESEARCH AND TRAINING)

INVESTIGATIONS BOOTCAMP NIBRT (NATIONAL INSTITUTE FOR BIO-PROCESSING RESEARCH AND TRAINING) INVESTIGATIONS BOOTCAMP IN PARTNERSHIP WITH NIBRT (NATIONAL INSTITUTE FOR BIO-PROCESSING RESEARCH AND TRAINING) Dates: January 29 th - 31 st, 2013 Time: 8:30am-5:30pm Venue: NIBRT, Dublin Training Outline

More information

Leachables and Extractables Outlook PODP Accomplishments and Next Steps

Leachables and Extractables Outlook PODP Accomplishments and Next Steps Leachables and Extractables Outlook PODP Accomplishments and Next Steps Diane M. Paskiet Associate Director of Scientific Affairs West PQRI PODP Workshop February 22-23, 2011 Improvement A Priori Reasoning

More information

BRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.

BRIEFING. . Over time, 466 may be used less frequently and may be withdrawn. Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities

More information

IMPURITIES IN NEW DRUG PRODUCTS

IMPURITIES IN NEW DRUG PRODUCTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for

More information

Pharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics. December 3-4, 2012 PERI Training Facility ~ Arlington, VA

Pharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics. December 3-4, 2012 PERI Training Facility ~ Arlington, VA Pharmceutical Toxicology: Tentative Agenda Pharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics December 3-4, 2012 PERI Training Facility ~ Arlington, VA Monday,

More information

Thursday, April 17, :30 pm to 9:00 pm UMass Lowell Emerging Technologies and Innovation Center 40 University Avenue Lowell, Massachusetts

Thursday, April 17, :30 pm to 9:00 pm UMass Lowell Emerging Technologies and Innovation Center 40 University Avenue Lowell, Massachusetts Want to participate in the UMass Dartmouth program but the UMD campus is too far away? Have we got a great idea for you! Join the Boston Area Chapter on April 17 th at U Mass Lowell and be part of several

More information

Integrating Toxicological Information Effectively Throughout Organizations. Joel Bercu PhD MPH DABT Director, Gilead Sciences

Integrating Toxicological Information Effectively Throughout Organizations. Joel Bercu PhD MPH DABT Director, Gilead Sciences Integrating Toxicological Information Effectively Throughout Organizations Joel Bercu PhD MPH DABT Director, Gilead Sciences Environmental and Occupational Toxicology Mission Protect patients, employees,

More information

Regulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA

Regulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is

More information

CTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016

CTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016 CTA/NDA Regulatory Landscape in China Jack Xie, PhD, DABT SOT 2016 Disclaimer The content of the following presentation represents solely author s view and may not reflect any position of Roche or China

More information

Extractable and Leachable Studies of Parenteral Infusion and Transfusion Products

Extractable and Leachable Studies of Parenteral Infusion and Transfusion Products Extractable and Leachable Studies of Parenteral Infusion and Transfusion Products Jianfeng Hong Fresenius Kabi USA LLC. 3 Corporate Drive, Lake Zurich, Illinois 60047, USA Overview Fresenius Kabi and Products.

More information

Modern Approaches to Process Understanding

Modern Approaches to Process Understanding Biomanufacturing and Process Development (BPD) Modern Approaches to Process Understanding Thursday, September 18, 2014 1:00 pm - Registration begins 1:15 5:00 pm - Presentations & Networking North Carolina

More information

Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA

Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA Overview of exploratory INDs Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT Office of New Drugs Center for Drug Evaluation

More information

ontainer Closure Systems

ontainer Closure Systems C PharmaED s Register by July 1 st and receive a $300 Discount! ontainer Closure Systems Strategies for Selection, Compliance and Mitigation of Extractables and Leachables Challenges SEPTEMBER 15-16, 2008,

More information

Scientific and Regulatory Perspectives on Measuring Protein Aggregation of Biotechnology Products

Scientific and Regulatory Perspectives on Measuring Protein Aggregation of Biotechnology Products Scientific and Regulatory Perspectives on Measuring Protein Aggregation of Biotechnology Products Ashutosh Rao, Ph.D. Chief, Laboratory of Applied Biochemistry Division of Biotechnology Review and Research

More information

Method Validation Studies How GLP Interacts With Guidance Documents

Method Validation Studies How GLP Interacts With Guidance Documents Method Validation Studies How GLP Interacts With Guidance Documents Steven S. Kuwahara ROBERT GEORGE YOUNG/GETTY IMAGES GLP Forum addresses topics of interest associated with good laboratory practices.

More information

Speakers Title & Biography

Speakers Title & Biography Speakers Title & Biography Dr. Janice M. Soreth Deputy Director, FDA Europe Office/CDER, Liaison to EMA Dr. Soreth 20-year agency veteran with unparalleled experience, including serving as CDER's director

More information

Stability Studies for Pharmaceutical Products (API and finished products)

Stability Studies for Pharmaceutical Products (API and finished products) A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry Stability Studies for Pharmaceutical Products (API and finished products)

More information

Harmonizing Standards and Specifications

Harmonizing Standards and Specifications WASHINGTON REPORT Harmonizing Standards and Specifications Jill Wechsler Manufacturers seek more FDA guidance about establishing product specifications during drug development as part of the agency s efforts

More information

Project Management for Human Resources

Project Management for Human Resources Project Management for Human Resources *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! HR Managers are asked to juggle a wide variety of assignments and add on special ones as needed.

More information

Threshold of Toxicological Concern Initiatives for Medical Devices Richard Hutchinson, DVM, PhD, DABT J&J Global Surgery Group.

Threshold of Toxicological Concern Initiatives for Medical Devices Richard Hutchinson, DVM, PhD, DABT J&J Global Surgery Group. Threshold of Toxicological Concern Initiatives for Medical Devices Richard Hutchinson, DVM, PhD, DABT J&J Global Surgery Group Abstract The Threshold of Toxicological Concern (TTC) is a concept used to

More information

From Conversation to Conservation

From Conversation to Conservation 6 TH ANNUAL CONNECTICUT FOREST CONSERVATION AND RESEARCH FORUM COOPERATIVE EXTENSION SYSTEM College of Agriculture and Natural Resources SOCIETY OF AMERICAN FORESTERS 1900 November 23, 2010 UNIVERSITY

More information

2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast

2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast 2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As

More information

Experiences with the adoption of the PQRI best practice guidelines when applied to development of an E&L development package for a DPI

Experiences with the adoption of the PQRI best practice guidelines when applied to development of an E&L development package for a DPI Experiences with the adoption of the PQRI best practice guidelines when applied to development of an E&L development package for a DPI March 2011 Anatomy of this presentation A personal list of highlights

More information

2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast

2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast 2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As

More information

2 Day Seminar. Supplier Management for Medical Device Manufacturers 12 RAPS CREDITS. Jun Boston

2 Day Seminar. Supplier Management for Medical Device Manufacturers 12 RAPS CREDITS. Jun Boston 2 Day Seminar Supplier Management for Medical Device Manufacturers 12 RAPS CREDITS Jun 01 02 Boston Seminar One Registration $ 993 Special Group Discount Register for Four attendees $ 3495 COURSE SUMMARY

More information

Introduction to Drug Design and Discovery

Introduction to Drug Design and Discovery Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,

More information

Issues in Cancer Drug Development of the Future. Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007

Issues in Cancer Drug Development of the Future. Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007 Issues in Cancer Drug Development of the Future Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007 Agenda: Scientific Issues n Why improve the quality of cancer clinical

More information

of the TTC Douglas J Ball, MS, DABT

of the TTC Douglas J Ball, MS, DABT Pharmaceutical Applications of the TTC Douglas J Ball, MS, DABT Agenda Derivation of the TTC Cramer Classification Application of the TTC ICH M7 Leachable and Extractable (L&E) Qualification Case studies

More information

OMICS International Conferences

OMICS International Conferences About OMICS Group OMICS Group is an amalgamation of Open Access Publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information

More information

MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT

MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT PharmaSUG Single Day Event Using Standards, Even for Non-Standard

More information

PQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products

PQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products PQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products Prepared by: Doug Ball (Pfizer), Diane Paskiet (West-Monarch), Daniel L.

More information

Developing a Phase-Appropriate Extractables and Leachables Program

Developing a Phase-Appropriate Extractables and Leachables Program LIFE SCIENCES HOW DO YOU PERFORM A SUCCESSFUL ILV? HOW DO YOU UNDERSTAND THE CAUSE OF A PAINT FAILURE? HOW DO YOU MEET GLOBAL REGULATORY REQUIREME U DETERMINE THE CAUSE OF LANDING GEAR FAILURE? HOW DO

More information

Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review

Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical

More information

Agreed with W. Cornell Graduate Program and Tri-I

Agreed with W. Cornell Graduate Program and Tri-I Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration

More information

DRUG SAFETY EVALUATION

DRUG SAFETY EVALUATION DRUG SAFETY EVALUATION DRUG SAFETY EVALUATION SHAYNE C. GAD A John Wiley & Sons, Inc., Publication This book is printed on acid-free paper. Copyright # 2002 by John Wiley and Sons, Inc., New York. All

More information

San Antonio Bay Partnership

San Antonio Bay Partnership June 27, 2017 9:00 am - 5:00 pm June 28, 2017 9:00 am - 12:45 pm The Needs Your Help! Established in 2010, the (SABP) is a regional, stakeholder-driven planning and management program that is focused on

More information

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more:

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right

More information

Regulatory Issues and Drug Product Approval for Biopharmaceuticals

Regulatory Issues and Drug Product Approval for Biopharmaceuticals Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop

More information

Biocompatibility Testing and Evaluations for Medical Devices

Biocompatibility Testing and Evaluations for Medical Devices Informa Life Sciences 7th Annual Biocompatibility Testing and Evaluations for Medical Devices 8-9 December 2015 Radisson Blu Royal Hotel, Dublin, Ireland Latest ISO 10993 updates and practical industry

More information

Expanded Access and the Individual Patient IND

Expanded Access and the Individual Patient IND Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office

More information

Introduction to CMC Regulatory Affairs

Introduction to CMC Regulatory Affairs Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4

More information

Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences

Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences Laurie Graham FDA/CDER Office of Pharmaceutical Quality (OPQ) Office of Policy for Pharmaceutical Quality (OPPQ) 1 Disclaimer

More information

A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy

A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy Nicholas Cappuccino, PhD Vice-President, Head of Quality and Scientific Affairs Dr. Reddy s Laboratories,

More information

3M Drug Delivery Systems. April 26, 2011

3M Drug Delivery Systems. April 26, 2011 3M MDI Manufacturing April 26, 2011 3M Drug Delivery Systems Drug Delivery Systems Overview 3M Drug Delivery Systems is a division of 3M that is dedicated to the development and manufacturing of inhalation

More information

2. Risk-based compliance was also a key component in the FDA's new approach for dealing with electronic records and signatures: 21 CFR Part 11.

2. Risk-based compliance was also a key component in the FDA's new approach for dealing with electronic records and signatures: 21 CFR Part 11. LITERATURE REVIEW: Risk management is well known and practiced in many industries and several industry task forces have developed guidance documents that facilitate risk management. Risk management for

More information

Managing QbD From A CMO Perspective

Managing QbD From A CMO Perspective Managing QbD From A CMO Perspective By Cathy Yarbrough The concepts and methods of Quality by Design (QbD), which the automobile, airline, and electronics industries have utilized to enhance the quality

More information

Extractables, Leachables, & Elemental Impurities 2018 West Coast

Extractables, Leachables, & Elemental Impurities 2018 West Coast Extractables, Leachables, & Elemental Impurities 2018 West Coast Ensuring Quality, Safety, and Regulatory Compliance for Drugs & Biologics November 13 14, 2018, Sheraton La Jolla, CA Featuring Lessons

More information

Teeramanas Tanaekakarapong, a peritoneal dialysis patient

Teeramanas Tanaekakarapong, a peritoneal dialysis patient Teeramanas Tanaekakarapong, a peritoneal dialysis patient Application of ICHQ9 Risk Management Principles to Assess the Risk of Leachables Adversely Impacting the Quality and/or Safety of Complex Biopharmaceuticals

More information

3M Purification Inc. Technical and Scientific Services Global Support for the Life Science Industry. Global Expertise delivered locally

3M Purification Inc. Technical and Scientific Services Global Support for the Life Science Industry. Global Expertise delivered locally 3M Purification Inc. Technical and Scientific Services Global Support for the Life Science Industry Global Expertise delivered locally Global expertise delivered locally As a global leader in measuring,

More information

Biocompatibility evaluation of breathing gas pathways in healthcare applications. Part 1: Evaluation and testing within a risk management process

Biocompatibility evaluation of breathing gas pathways in healthcare applications. Part 1: Evaluation and testing within a risk management process Provläsningsexemplar / Preview INTERNATIONAL STANDARD ISO 18562-1 First edition 2017-03 Biocompatibility evaluation of breathing gas pathways in healthcare applications Part 1: Evaluation and testing within

More information

New Drug Product Impurities

New Drug Product Impurities Title Page Image - with courtesy of the FDA CDER original web site at www. cder.fda.gov/ New Drug Product Impurities IAGIM Scientific Committee Block JD; Holmann E ; West P NEW DRAFT GUIDANCE FDA Viewpoint

More information

Disinfectant Qualification and Cleanroom Disinfection A Step by Step Workshop

Disinfectant Qualification and Cleanroom Disinfection A Step by Step Workshop Microrite, Inc. brings you this unique advanced course in ; part of Microrite s Step by Step Workshop Series Participate in the only workshop which will guide you through the process of choosing a cost

More information

NINDS/HEAL Biomarker Programs New Biomarker Initiatives at NIH: Neurological Disorders and Pain

NINDS/HEAL Biomarker Programs New Biomarker Initiatives at NIH: Neurological Disorders and Pain NINDS/HEAL Biomarker Programs New Biomarker Initiatives at NIH: Neurological Disorders and Pain OCTOBER 30, 2018 Mary Ann Pelleymounter, PhD Program Director mary.pelleymounter@nih.gov 1 About the Speaker

More information

Dealing with Extractables & Leachables from a Regulatory Perspective - Design of Extractables & Leachables Studies - Safety Assessment of Leachables

Dealing with Extractables & Leachables from a Regulatory Perspective - Design of Extractables & Leachables Studies - Safety Assessment of Leachables Dealing with Extractables & Leachables from a Regulatory Perspective - Design of Extractables & Leachables Studies - Safety Assessment of Leachables Timothy W. Robison, Ph.D., D.A.B.T. Division of Pulmonary,

More information

Why Does a Project Need a Project Manager and a Business Analyst? 1 Powered by POeT Solvers Limited

Why Does a Project Need a Project Manager and a Business Analyst? 1  Powered by POeT Solvers Limited Why Does a Project Need a Project Manager and a Business Analyst? 1 www.pmtutor.org Powered by POeT Solvers Limited Agenda What Is A Business Analyst? Why Does A Project Need A Project Manager And A Business

More information

EBC Series with MassDEP Regional Leadership Commissioner Suuberg and the Northeast Region Leadership Team Hot Issues & Ongoing Challenges

EBC Series with MassDEP Regional Leadership Commissioner Suuberg and the Northeast Region Leadership Team Hot Issues & Ongoing Challenges EBC Series with MassDEP Regional Leadership Commissioner Suuberg and the Northeast Region Leadership Team Hot Issues & Ongoing Challenges Wednesday, October 24, 2018 McLane Middleton Woburn, Massachusetts

More information

EFFECTIVE CLINICAL TRIALS. NUSAGE PharmEng. Pharmaceutical and Biotechnology Training Program. Copyright 2014 NUSAGE-PharmEng.

EFFECTIVE CLINICAL TRIALS. NUSAGE PharmEng. Pharmaceutical and Biotechnology Training Program.  Copyright 2014 NUSAGE-PharmEng. EFFECTIVE CLINICAL TRIALS NUSAGE PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry EFFECTIVE CLINICAL TRIALS Objective The intent

More information

Strategic Outsourcing for Success

Strategic Outsourcing for Success Strategic Outsourcing for Success Improving Speed to Clinic using External Sourcing Massachusetts Biotechnology Council Meeting November 16, 2012 Cambridge, MA BioProcess Technology Consultants www.bptc.com

More information

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing By Impact Analytical Introduction About Impact Analytical Impact Analytical is a contract analytical testing

More information

Toxic Pollution from Powerplants: Large Emissions, Little Risk

Toxic Pollution from Powerplants: Large Emissions, Little Risk Harvard Center for Risk Analysis APRIL 1999 Volume 7 Issue 2 Risk in Perspective Toxic Pollution from Powerplants: Large Emissions, Little Risk George M. Gray, Ph.D. Although this industry will report

More information

American Association of Pharmaceutical Scientists (AAPS)

American Association of Pharmaceutical Scientists (AAPS) American Association of Pharmaceutical Scientists (AAPS) AAPS, King Street, Alexandria, VA, USA* he American Association of Pharmaceu- Scientists (AAPS), founded in 1986, Ttical is an individual membership

More information

Precision. Proficiency. Proximity.

Precision. Proficiency. Proximity. Precision. Proficiency. Proximity. Precision Accuracy in testing is paramount to ensuring product safety and efficacy. And fast turnaround times are critical to keeping your project on schedule. With

More information

Analytical Methods Development and Validation

Analytical Methods Development and Validation Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the

More information

Key multiplicity concepts and principles addressed in the Draft Guidance: Multiple Endpoints in Clinical Trials

Key multiplicity concepts and principles addressed in the Draft Guidance: Multiple Endpoints in Clinical Trials Key multiplicity concepts and principles addressed in the Draft Guidance: Multiple Endpoints in Clinical Trials Mohammad F. Huque, Ph.D. Office of Biostatistics OTS, CDER/FDA DIA Annual Meeting, Boston,

More information

GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives

GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives Stephen Miller, Ph.D. CMC-Lead; Office of New Drug Products Office of Pharmaceutical Quality

More information

Acceptable Intake (AI) and Permitted Daily Exposure (PDE) Data Sharing Project for Pharmaceutical Impurities

Acceptable Intake (AI) and Permitted Daily Exposure (PDE) Data Sharing Project for Pharmaceutical Impurities Acceptable Intake (AI) and Permitted Daily Exposure (PDE) Data Sharing Project for Pharmaceutical Impurities Dr. William Drewe Business Development Manager David Wilkinson Senior Data Scientist Agenda

More information

CHANGE CONTROL MANAGEMENT FOR A STABILITY PROGRAM

CHANGE CONTROL MANAGEMENT FOR A STABILITY PROGRAM Potential Changes and Minimizing the Impact of Registration CHANGE CONTROL MANAGEMENT FOR A STABILITY PROGRAM Kim Huynh Ba Eecutive Director PHARMALYTIK www.pharmalytik.com Biography Kim Huynh Ba has over

More information

Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim

Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim S Blech EBF Focus Workshop: Metabolite Profiling and Quantification Strategies in Drug R&D Sep 25,

More information

Reference Standards for Monoclonal Antibodies: Key Challenges Addressed

Reference Standards for Monoclonal Antibodies: Key Challenges Addressed CASSS WCBP 2012: 16th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products January 23-25, 2012 Reference Standards for Monoclonal Antibodies: Key Challenges

More information

WELCOME TO THE SCOND ANNUAL: 2016 Waters Corporation 1

WELCOME TO THE SCOND ANNUAL: 2016 Waters Corporation 1 WELCOME TO THE SCOND ANNUAL: 2016 Waters Corporation 1 Identification and Quantification of Unwanted Substances in Contact Materials WELCOME 2016 Waters Corporation 2 INTRODUCTION Your Hosts Latest developments

More information

LAB EXPERTS AT YOUR SIDE Over twenty years of experience

LAB EXPERTS AT YOUR SIDE Over twenty years of experience LAB EXPERTS AT YOUR SIDE Over twenty years of experience About us SYNLAB Pharma offers a broad range of laboratory services to the biotechnology, pharmaceutical and cosmetic industries as well as to manufacturers

More information

About Clinical Trials: What They Can Mean For You?

About Clinical Trials: What They Can Mean For You? About Clinical Trials: What They Can Mean For You? Karl Cremer, PharmD and AnnKatrin Petersen, MD, MS January 25, 2012 ClinicalStudy.org Owned and operated by PRI, Inc. 5927 Balfour Court, Suite 201 Carlsbad,

More information

A PMP Among PhDs: Applying Program Management to Biotechnology Research and Commercialization Speaker: Jill Almaguer, PE, MBA, PMP Company: Texas

A PMP Among PhDs: Applying Program Management to Biotechnology Research and Commercialization Speaker: Jill Almaguer, PE, MBA, PMP Company: Texas A PMP Among PhDs: Applying Program Management to Biotechnology Research and Commercialization Speaker: Jill Almaguer, PE, MBA, PMP Company: Texas Heart Institute Website: www.texasheart.org, www.ccobtexas.org

More information

Documentation requirements for an initial consultation

Documentation requirements for an initial consultation Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,

More information

CMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.

CMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. CMC Considerations for 505(b)(2) Applications Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011 1 Introduction Outline Brief overview of FDA drug approval pathways

More information

PHARMACEUTICAL TESTING

PHARMACEUTICAL TESTING WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey

More information

Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry

Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast

2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast 2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As

More information